Last reviewed · How we verify
Continuous infusion of beta-lactam antibiotics .
At a glance
| Generic name | Continuous infusion of beta-lactam antibiotics . |
|---|---|
| Also known as | Benzylpenicillin, Ampicillin, Dicloxacillin, Piperacillin/tazobactam, Cefuroxime |
| Sponsor | Sara Thønnings |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis (PHASE4)
- Therapeutic Options for CRAB (PHASE4)
- Enhanced Molecular Microbiological Surveillance Versus Ceftriaxone Prophylaxis in Hematopoietic Cell Transplant Patients (NA)
- Bolus Versus Continuous Infusion of Meropenem (PHASE4)
- Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis. (PHASE4)
- Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (PHASE4)
- Target Attainment of Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM vs. Standard of Care Treatment in Patients With Complicated S. Aureus Infection (PHASE2)
- A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: